Boehringer Ingelheim Advances Potential First-in-Class Triple Receptor Agonist BI 3034701 to Phase 2 for Obesity

Boehringer Ingelheim has begun a phase 2 clinical trial of BI 3034701, an investigational triple glucagon-like peptide-1 (GLP-1)/glucose-dependent insulinotropic polypeptide (GIP)/neuropeptide Y2 (NPY2) receptor agonist, in adults with obesity and overweight, the company announced on July 16, 2026.¹ The trial, registered as NCT07662122, follows a phase 1 program in which BI 3034701 showed a generally favorable safety and tolerability profile.¹,⁴ If successful, BI 3034701 would add a third, differentiated hunger-signaling pathway to the GLP-1/GIP mechanisms that underlie currently marketed obesity therapies.¹,²,³

"The obesity treatment landscape is rapidly expanding, with a need to target a broader variety of therapeutic mechanisms given that obesity is a heterogeneous disease," said Ania Jaestreboff, MD, PhD, professor at Yale School of Medicine and director of the Yale Obesity Research Center (Y-Weight), in a company press release.¹ "This approach may better enable healthcare providers to move towards matching the right treatment to the right patient at the right time."

Why does BI 3034701's triple-receptor design matter?

BI 3034701 is designed to activate the GLP-1, GIP, and NPY2 receptors simultaneously.¹ The GLP-1 and GIP components engage pathways already established to drive satiety, weight reduction, and metabolic regulation in approved obesity therapies.²,³ NPY2 receptor agonism is a less established, potentially differentiating mechanism: preclinical research indicates NPY2 receptor activation modulates central hunger signaling, though its broader effect on eating behavior remains under investigation.³

In phase 1 testing, BI 3034701 demonstrated a generally favorable safety and tolerability profile, supporting its advancement into phase 2.¹,⁴ The phase 2 study is designed to evaluate the molecule in people with obesity and overweight, including dose-finding and broader assessment of efficacy and safety; results have not yet been reported.

What is the burden of obesity, and how does BI 3034701 fit the treatment landscape?

Obesity is a complex, chronic disease affecting more than 1 in 8 people worldwide, with heterogeneous drivers that create a need for multiple therapeutic mechanisms rather than a single approach.¹ More than 1 billion people globally live with obesity today, and that figure could more than double from 2010 levels by 2030.¹

BI 3034701 sits within Boehringer Ingelheim's broader obesity and cardiometabolic pipeline, which also includes survodutide, a dual glucagon/GLP-1 receptor agonist with recently presented phase 3 data, plus additional investigational and oral treatment approaches.¹

How are company and independent voices framing this development?

Shashank Deshpande, chairman of the board of managing directors and head of Human Pharma at Boehringer Ingelheim, said the company is "working towards a future where earlier, multi-pathway intervention leads to long-term outcomes that prevent the progression of interconnected cardiometabolic diseases."¹ He added that the company aims for BI 3034701 to "go beyond short-term weight loss and address both the biological and behavioral drivers of obesity."¹

Because NPY2-driven mechanisms have not yet been evaluated in large clinical trials, independent confirmation of efficacy, durability, and behavioral effects would be needed before the differentiated mechanism can be considered clinically validated.

What are the limitations and next steps?

BI 3034701 remains in early clinical development, with efficacy and safety data are limited to phase 1 findings, and phase 2 results are not yet available.¹^,⁴

Data from the phase 2 study, once available, will need to clarify weight-loss magnitude, safety across doses, and how NPY2 agonism performs relative to established GLP-1/GIP-based therapies.

References

1. Boehringer Ingelheim. Boehringer Ingelheim strengthens obesity pipeline as potential first-in-class triple receptor agonist BI 3034701 enters Phase II development. Published July 16, 2026. Accessed July 16, 2026. https://www.boehringer-ingelheim.com/human-health/crm-health/metabolic-health/obesity-potential-first-class-triple-receptor-agonist-phase-2
2. Shah M, Vella A. Effects of GLP-1 on appetite and weight. Rev Endocr Metab Disord. 2014;15(3):181-187. doi:10.1007/s11154-014-9289-5
3. Borner T, Geisler CE, Fortin SM, et al. GIP receptor agonism attenuates GLP-1 receptor agonist-induced nausea and emesis in preclinical models. Diabetes. 2021;70(11):2545-2553. doi:10.2337/db21-0459
4. ClinicalTrials.gov. A study to test whether BI 3034701 helps people to lose weight who live with obesity or overweight. NCT07662122. Updated July 9, 2026. Accessed July 16, 2026. https://clinicaltrials.gov/study/NCT07662122